This study examined possible relationships between homocysteine and markers used in first-trimester screening for Down syndrome. Pregnancies were categorized into 4 groups according to quartile ranking of maternal plasma homocysteine concentration. Of the 595 pregnancies, 147 were assigned to group 1 (homocysteine level 0.6-3.5 μmol/L), 156 to group 2 (homocysteine level 3.6-4.5 μmol/L), 142 to group 3 (homocysteine level 4.6-5.6 μmol/L), and 150 pregnancies to group 4 (homocysteine level 5.7-12.6 μmol/L). No significant difference in mean nuchal translucency and mean free β-human chorionic gonadotropin (free-βhCG) multiples of the median (MoM) levels were observed. However, the mean pregnancy-associated plasma protein A (PAPP-A) MoM levels were significantly decreased in inverse relationship with homocysteine level among all 4 groups (F = 31.127, P < .001). If homocysteine is assayed as part of the first-trimester maternal serum testing, it is important to adjust for homocysteine concentration when using PAPP-A serum level for calculating the risk of fetal aneuploidy.
Shaw SW, Hsu JJ, Lee CN, et al. First- and second-trimester Down syndrome screening: current strategies and clinical guidelines. Taiwan J Obstet Gynecol . 2008;47(2):157-162.
2.
Gagnon A., Wilson RD, Audibert F., et al. Society of Obstetricians and Gynaecologists of Canada Genetics Committee. Obstetrical complications associated with abnormal maternal serum markers analytes. J Obstet Gynaecol Can. 2008 ;30(10):918-949.
3.
Wu AHMarkers for early detection of cardiac diseases. Scand J Clin Lab Invest Suppl. 2005;65(suppl 240):112-121.
4.
Wierzbicki ASHomocysteine and cardiovascular disease: a review of the evidence. Diab Vasc Dis Res. 2007;4(2):143-150.
5.
Daly S., Cotter A., Molloy AE, Scott J.Homocysteine and folic acid: implications for pregnancy. Semin Vasc Med. 2005;5(2): 190-200.
6.
Cheng PJ, Liu CM, Chueh HY, Lin CM, Soong YKFirst-trimester nuchal translucency measurement and echocardiography at 16 to 18 weeks of gestation in prenatal detection for trisomy 18. Prenat Diagn. 2003;23(3):248-251.
7.
Cheng PJ, Chang SD, Shaw SW, Soong YKNuchal translucency thickness in fetuses with chromosomal translocation at 11-12 weeks of gestation. Obstet Gynecol. 2005;105(5 pt 1):1058-1062.
8.
Cheng PJ, Shaw SW, Soong YKAssociation of fetal choroid plexus cysts with trisomy 18 in a population previously screened by nuchal translucency thickness measurement. J Soc Gynecol Investig. 2006;13(4):280-284.
9.
Lawrence JB, Oxvig C., Overgaard MT, et al. The insulin-like growth factor (IGF)-dependent IGF binding protein-4 protease secreted by human fibroblasts is pregnancy-associated plasma protein-A . Proc Natl Acad Sci U S A. 1999;96(6):3149-3153.
10.
Graham I.Homocysteine in health and disease. Ann Intern Med. 1999;131(5):387-388.
11.
Kluijtmans LA, Young IS, Boreham CA, et al. Genetic and nutritional factors contributing to hyperhomocysteinemia in young adults. Blood. 2003;101(7):2483-2488.
12.
Kim KN, Kim YJ, Chang N.Effects of the interaction between the C677T 5,10-methylenetetrahydrofolate reductase polymorphism and serum B vitamins on homocysteine levels in pregnant women. Eur J Clin Nutr. 2004;58(1):10-16.
13.
Tanaka T., Scheet P., Giusti B., et al. Genome-wide association study of vitamin B6, vitamin B12, folate, and homocysteine blood concentrations. Am J Hum Genet.2009;84(4):477-482.
14.
Selhub J. Folate, vitamin B12 and vitamin B6 and one carbon metabolism. J Nutr Health Aging. 2002;6(1):39-42.
15.
Graham CH, Hawley TS, Hawley RG, et al. Establishment and characterization of first trimester human trophoblast cells with extended lifespan. Exp Cell Res. 1993;206(2):204-211.
16.
Dugoff L., Hobbins JC, Malone FD, et al. First-trimester maternal serum PAPP-A and free-beta subunit human chorionic gonadotropin concentrations and nuchal translucency are associated with obstetric complications: a population-based screening study (the FASTER Trial). Am J Obstet Gynecol. 2004;191(4):1446-1451.
17.
Spencer CA, Allen VM, Flowerdew G., Dooley K., Dodds L.Low levels of maternal serum PAPP-A in early pregnancy and the risk of adverse outcomes. Prenat Diagn. 2008;28(11):1029-1036.
18.
Dodds L., Fell DB, Dooley KC, et al. Effect of homocysteine concentration in early pregnancy on gestational hypertensive disorders and other pregnancy outcomes. Clin Chem. 2008;54(2):326-334.
19.
Hoque MM, Bulbul T., Mahal M., Islam NA, Ferdausi M.Serum homocysteine in pre-eclampsia and eclampsia. Bangladesh Med Res Counc Bull. 2008;34(1):16-20.
20.
Scholl TO, Johnson WGFolic acid: influence on the outcome of pregnancy. Am J Clin Nutr. 2000;71(5 suppl):1295S-1303S.
21.
Tul N., Pusenjak S., Osredkar J., Spencer K., Novak-Antolic Z. Predicting complications of pregnancy with first-trimester maternal serum free-betahCG, PAPP-A and inhibin-A. Prenat Diagn. 2003;23(12):990-996.
22.
Smith GC, Shah I., Crossley JA, et al. Pregnancy-associated plasma protein A and alpha-fetoprotein and prediction of adverse perinatal outcome. Obstet Gynecol . 2006;107(1):161-166.
23.
Pilalis A., Souka AP, Antsaklis P., et al. Screening for pre-eclampsia and fetal growth restriction by uterine artery Doppler and PAPP-A at 11-14 weeks’ gestation. Ultrasound Obstet Gynecol. 2007;29(2):135-140.
24.
Bartels I., Thiele M., Bogart MHMaternal serum hCG and SP1 in pregnancies with fetal aneuploidy. Am J Med Genet. 1990;37(2): 261-264.
25.
Hay DLPlacental histology and the production of human choriogonadotrophin and its subunits in pregnancy. Br J Obstet Gynaecol. 1988;95(12):1268-1275.
